Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
Japan’s Fiscal System Council has reiterated its call for the full implementation of the FY2027 off-year drug price revision, saying it should proceed under the same framework as regular biennial revisions rather than with a narrower scope. The so-called “spring…
To read the full story
Related Article
- MOF Pushes for Full-Scale FY2027 Off-Year Drug Price Revision Ahead of “Spring” Proposal
April 28, 2026
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
- MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
- MOF Panel Urges Full-Scale Off-Year Revisions, Enhanced CEA: “Spring” Proposal
May 22, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
REGULATORY
- Govt to Explore Greater Rewards for Innovative Drugs in Honebuto
June 29, 2026
- MOF Panel Renews Push for Full-Scale Off-Year Revision in FY2027
June 29, 2026
- Government Unveils Four-Chapter Outline for 2026 Honebuto
June 26, 2026
- LDP, Ishin Leave Chuikyo Reform to Party Negotiators after Talks Stall
June 26, 2026
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…